Obstetrics and gynecology
-
Obstetrics and gynecology · Sep 2020
Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix.
To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30). ⋯ AbbVie Inc.
-
Obstetrics and gynecology · Sep 2020
Re-examining the Meis Trial for Evidence of False-Positive Results.
U. S. Food and Drug Administration (FDA)-approved 17α-hydroxyprogesterone caproate therapy is currently available to reduce recurrent preterm birth in the United States. ⋯ We assert PROLONG was underpowered, based on substantially lower observed preterm birth rates than anticipated, and therefore was a false-negative study, rather than the Meis trial being a false-positive study. Careful assessment of these two trials is critical as removal of 17α-hydroxyprogesterone caproate from the U. S. marketplace may have substantial effects on public health.
-
Obstetrics and gynecology · Sep 2020
Comparative Study Observational StudyNeonatal and Maternal Composite Adverse Outcomes Among Low-Risk Nulliparous Women Compared With Multiparous Women at 39-41 Weeks of Gestation.
To estimate whether the frequency of adverse maternal and neonatal outcomes differs between low-risk nulliparous and multiparous women at 39-41 weeks of gestation. ⋯ The risk of composite adverse outcomes and SGA among low-risk nulliparous women at 39-41 weeks of gestation is significantly higher than among multiparous counterparts. However, nulliparous women had a lower risk of shoulder dystocia with maneuvers and LGA.